Thomas Jonassen
Direttore Tecnico/Scientifico/R&S presso SYNACT PHARMA AB
Posizioni attive di Thomas Jonassen
Società | Posizione | Inizio | Fine |
---|---|---|---|
SYNACT PHARMA AB | Direttore Tecnico/Scientifico/R&S | - | - |
Direttore/Membro del Consiglio | - | 20/03/2024 | |
University of Copenhagen | Corporate Officer/Principal | - | - |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Direttore Tecnico/Scientifico/R&S | - | - |
Fondatore | - | - |
Storia della carriera di Thomas Jonassen
Precedenti posizioni note di Thomas Jonassen
Società | Posizione | Inizio | Fine |
---|---|---|---|
TXP Pharma GmbH | Fondatore | - | - |
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Direttore Tecnico/Scientifico/R&S | 05/06/2009 | - |
Fondatore | 01/01/2000 | - |
Formazione di Thomas Jonassen
University of Copenhagen | Doctorate Degree |
Statistiche
Distribuzione geografica
Danimarca | 4 |
Svezia | 2 |
Germania | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Founder | 3 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SYNACT PHARMA AB | Health Technology |
Aziende private | 3 |
---|---|
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Health Technology |
TXP Pharma GmbH |
- Borsa valori
- Insiders
- Thomas Jonassen
- Esperienza